Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Androgen receptor drives cellular senescence.

Mirochnik Y, Veliceasa D, Williams L, Maxwell K, Yemelyanov A, Budunova I, Volpert OV.

PLoS One. 2012;7(3):e31052. doi: 10.1371/journal.pone.0031052. Epub 2012 Mar 5.

2.

Targeting prostate cancer angiogenesis through metastasis-associated protein 1 (MTA1).

Kai L, Wang J, Ivanovic M, Chung YT, Laskin WB, Schulze-Hoepfner F, Mirochnik Y, Satcher RL Jr, Levenson AS.

Prostate. 2011 Feb 15;71(3):268-80. doi: 10.1002/pros.21240. Epub 2010 Aug 17.

PMID:
20717904
3.

NF-kappaB balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement.

Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sánchez-Martinez C, Renault MA, Losordo D, Volpert OV.

Blood. 2010 Jul 22;116(3):475-84. doi: 10.1182/blood-2009-07-232132. Epub 2010 Mar 4. Erratum in: Blood. 2010 Dec 2;116(23):5079. Aurora, Aryn B [corrected to Aurora, Arin B].

4.

Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth.

Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A, Shifrin V, Beckmann R, Polsky C, Volpert OV.

Clin Cancer Res. 2009 Mar 1;15(5):1655-63. doi: 10.1158/1078-0432.CCR-08-2113. Epub 2009 Feb 17.

5.

Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Mirochnik Y, Kwiatek A, Volpert OV.

Curr Drug Targets. 2008 Oct;9(10):851-62. Review.

6.

Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.

Mirochnik Y, Rubenstein M, Guinan P.

J Drug Target. 2007 Jun;15(5):342-50.

PMID:
17541843
7.

Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo.

Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z, Volpert OV.

Int J Cancer. 2007 Sep 1;121(5):999-1008.

8.

Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer.

Filleur S, Volz K, Nelius T, Mirochnik Y, Huang H, Zaichuk TA, Aymerich MS, Becerra SP, Yap R, Veliceasa D, Shroff EH, Volpert OV.

Cancer Res. 2005 Jun 15;65(12):5144-52.

9.
10.

Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.

Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P.

Med Oncol. 2003;20(1):29-35.

PMID:
12665682
11.
12.

Effect of relaxin in two models of renal mass reduction.

Garber SL, Mirochnik Y, Brecklin C, Slobodskoy L, Arruda JA, Dunea G.

Am J Nephrol. 2003 Jan-Feb;23(1):8-12.

13.

Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines.

Rubenstein M, Mirochnik Y, Slobodskoy L, Guinan P.

Methods Find Exp Clin Pharmacol. 2001 Nov;23(9):487-90.

PMID:
11876021
14.
15.

Relaxin decreases renal interstitial fibrosis and slows progression of renal disease.

Garber SL, Mirochnik Y, Brecklin CS, Unemori EN, Singh AK, Slobodskoy L, Grove BH, Arruda JA, Dunea G.

Kidney Int. 2001 Mar;59(3):876-82.

16.

Differential effects of enalapril and irbesartan in experimental papillary necrosis.

Garber SL, Mirochnik Y, Arruda JA, Dunea G, Slobodskoy L.

Kidney Blood Press Res. 2001;24(1):39-43.

17.

In vivo establishment of T98G human glioblastoma.

Rubenstein M, Shaw M, Mirochnik Y, Slobodskoy L, Glick R, Lichtor T, Chou P, Guinan P.

Methods Find Exp Clin Pharmacol. 1999 Jul-Aug;21(6):391-3.

PMID:
10445230
18.

Evolution of experimentally induced papillary necrosis to focal segmental glomerulosclerosis and nephrotic proteinuria.

Garber SL, Mirochnik Y, Arruda JA, Dunea G.

Am J Kidney Dis. 1999 Jun;33(6):1033-9.

PMID:
10352190
19.

Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides.

Rubenstein M, Mirochnik Y, Chou P, Guinan P.

Methods Find Exp Clin Pharmacol. 1998 Dec;20(10):825-31.

PMID:
10091218
20.

Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.

Guinan P, Shaw M, Mirochnik Y, Slobodskoy L, Ray V, Rubenstein M.

Methods Find Exp Clin Pharmacol. 1998 Nov;20(9):739-42.

PMID:
10022026
21.

Angiotensin-converting enzyme inhibition reduces the effect of bromoethylamine-induced papillary necrosis and renal fibrosis.

Garber SL, Mirochnik Y, Desai SS, Arruda JA, Dunea G.

J Am Soc Nephrol. 1998 Jun;9(6):1052-9.

22.

Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.

Shaw M, Ratanawong S, Chou P, Ray V, Mirochnik Y, Slobodskoy L, Rubenstein M, Guinan P.

Methods Find Exp Clin Pharmacol. 1998 Mar;20(2):111-4.

PMID:
9604852
23.
24.

An evaluation of the markers p53 and Ki-67 for their predictive value in prostate cancer.

Uzoaru I, Rubenstein M, Mirochnik Y, Slobodskoy L, Shaw M, Guinan P.

J Surg Oncol. 1998 Jan;67(1):33-7. Review.

PMID:
9457254
25.

Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation.

Rubenstein M, Chou P, Mirochnik Y, Guinan P.

Med Oncol. 1997 Mar;14(1):23-9.

PMID:
9232607
26.

Antitumor effect of CPT-11, a new derivative of camptothecin, against human prostate cancer (PC-3) in vitro and prostate rat tumor (AT-3) in vivo.

Lievano G, Mirochnik Y, Rubenstein M, Shaw M, Guinan P.

Methods Find Exp Clin Pharmacol. 1996 Dec;18(10):659-62.

PMID:
9121221
27.

Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice.

Rubenstein M, Mirochnik Y, Chou P, Guinan P.

J Surg Oncol. 1996 Jul;62(3):194-200.

PMID:
8667627

Supplemental Content

Loading ...
Support Center